1. 4PNovel applications of MVA to improve outcomes in immunooncology. (27th February 2019) Authors: Heery, C; Pico-Navarro, C; Adams, T; Bauman, L; Medina, J; Hinterberger, M; Heiseke, A; Lauterbach, H; Hochrein, H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 52PA novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors. (5th March 2018) Authors: Medina, J; Hinterberger, M; Testori, M; Geiger, M; Giessel, R; Chaplin, P; Hochrein, H; Lauterbach, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P04.02 A novel cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies. (1st October 2020) Authors: Hinterberger, M; Medina-Echeverz, J; Testori, M; Geiger, M; Giessel, R; Bathke, B; Kassub, R; Gräbnitz, F; Fiore, G; Wennier, S; Chaplin, P; Suter, M; Hochrein, H; Lauterbach, H Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗